Pandemic-response adenoviral vector and RNA vaccine manufacturing
Pandemic-response adenoviral vector and RNA vaccine manufacturing
复制标题
应对流行病的腺病毒载体和 RNA 疫苗的制造
DOI：
10.1101/2021.08.20.21262370
复制
发表时间：
2021
期刊：
影响因子：
9.2
通讯作者：
C. Kontoravdi
中科院分区：
文献类型：
--
作者：
Z. Kis;K. Tak;D. Ibrahim;M. Papathanasiou;B. Chachuat;N. Shah;C. Kontoravdi
通过大规模疫苗接种快速应对全球COVID-19大流行目前受到疫苗生产速度的限制。本研究对COVID-19大流行期间部署的三种疫苗生产平台技术进行了技术经济可行性评估和比较：（1）腺病毒载体（AVV）疫苗，（2）信使RNA（mRNA）疫苗，以及（3）较新的自扩增RNA（saRNA）疫苗。除了评估生产过程的基线性能外，还使用基于方差的全局敏感性分析量化了关键设计和操作不确定性对这些疫苗平台的生产力和成本性能的影响。计算了生产数十亿剂疫苗以满足当前全球需求短缺和提供年度加强免疫的成本和资源需求预测。鉴于这些疫苗生产平台的疾病不可知性，基于模型的评估为政策制定者和疫苗制造商提供了关键见解，用于风险分析、资产利用、未来技术改进方向和未来流行病/大流行病准备。
Rapid global COVID-19 pandemic response by mass vaccination is currently limited by the rate of vaccine manufacturing. This study presents a techno-economic feasibility assessment and comparison of three vaccine production platform technologies deployed during the COVID-19 pandemic: (1) adenovirus-vectored (AVV) vaccines, (2) messenger RNA (mRNA) vaccines, and (3) the newer self-amplifying RNA (saRNA) vaccines. Besides assessing the baseline performance of the production process, impact of key design and operational uncertainties on the productivity and cost performance of these vaccine platforms is quantified using variance-based global sensitivity analysis. Cost and resource requirement projections are computed for manufacturing multi-billion vaccine doses for covering the current global demand shortage and for providing annual booster immunisations. The model-based assessment provides key insights to policymakers and vaccine manufacturers for risk analysis, asset utilisation, directions for future technology improvements and future epidemic/pandemic preparedness, given the disease-agnostic nature of these vaccine production platforms.
影响因子：
10.8
作者：
Shepherd, Sarah J.;Warzecha, Claude C.;Mitchell, Michael J.
通讯作者：
Mitchell, Michael J.
影响因子：
8.1
作者：
Kucherenko, Sergei;Feil, Balazs;Mauntz, Wolfgang
通讯作者：
Mauntz, Wolfgang